New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
05:55 EDTABMD, ABMD, ABMD, ANGO, ANGO, ANGO, BAX, BAX, BAX, BDX, BDX, BDX, CAH, CAH, CAH, COV, COV, COV, EW, EW, EW, NVO, NVO, NVO, SYK, SYK, SYKSociety of Thoracic Surgeons to hold annual meeting
49th Annual Meeting of the STS is being held in Los Angeles on January 26-30.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 15, 2015
08:13 EDTBAXCoherus, Baxter announce amendment to etanercept biosimilar agreement
Coherus BioSciences (CHRS) and Baxter International (BAX) announced that they have amended certain financial terms of their collaboration agreement established in August 2013 regarding the development and commercialization of CHS-0214, an etanercept biosimilar product candidate, for Europe, Canada, Brazil, and certain other markets. Under the terms of the amended agreement, certain existing milestones and funding obligations have been revised, and the collaboration has been expanded to include select pre-commercialization activities. In aggregate, the revised milestone payments may exceed the previous Baxter funding obligations by approximately $12M. Additionally, Baxter has agreed to purchase Coherus common stock in a private placement transaction. All other contractual provisions remain materially unchanged.
07:41 EDTNVOEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
14:48 EDTSYKZimmer, Stryker have mixed read through from J&J results, says Wells Fargo
Subscribe for More Information
07:38 EDTBAXBaxter removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
07:05 EDTANGONeedham to hold a conference
Subscribe for More Information
April 13, 2015
14:07 EDTCAHEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
10:15 EDTSYKHigh option volume stocks
Subscribe for More Information
April 10, 2015
16:14 EDTANGOOn The Fly: Closing Wrap
Subscribe for More Information
08:51 EDTBAXBaxter initiates voluntary recall of select lots of IV solutions
Subscribe for More Information
08:38 EDTANGOAngioDynamics weakness a buying opportunity, says Canaccord
Canaccord said the weakness in AngioDynamics following its soft Q3 results is a buying opportunity. The firm cited negative currency impact, a slowdown in EVLT procedures, its Morpheus PICC market withdrawal, and the delay in its second generation AngioVac release. Canaccord likes the company's free cash flow generation and improved inventory management and reiterated its Buy rating, but lowered its price target to $20 from $22 on AngioDynamics shares.
07:35 EDTEWExpert comments bullish for Edwards, Medtronic, says RBC Capital
Subscribe for More Information
April 9, 2015
16:44 EDTANGOAngioDynamics down 6% after weaker than expected Q3 results, guidance
Subscribe for More Information
16:09 EDTANGOAngioDynamics re-entering embolization market with EmboMedics pact
Subscribe for More Information
16:06 EDTANGOAngioDynamics now sees FY15 adjusted EPS 57c-60c, consensus 68c
Subscribe for More Information
16:06 EDTANGOAngioDynamics lowers FY15 revenue view to $356M-$360M from $362M-$368M
The company said, "We believe the action we took in the third fiscal quarter to voluntary recall/discontinue our Morpheus PICC product line will drive longer-term strategic benefits; however, its short term impact coupled with the headwinds due to foreign currency exchange has resulted in a revision of net sales for fiscal year 2015 to a range of $356M-$360M from our prior outlook of a range of $362M-$368M. At the midpoint, excluding the supply agreement and based on constant currency, this represents an increase of 3% over fiscal year 2014."
16:05 EDTANGOAngioDynamics sees Q4 adjusted EPS 13c-16c, consensus 19c
Sees Q4 revenue $90M-$94M, 3% at the top end on a constant currency basis and excluding its supply agreement.
16:03 EDTANGOAngioDynamics reports Q3 adjusted EPS 12c, consensus 16c
Subscribe for More Information
15:20 EDTANGONotable companies reporting after market close
Subscribe for More Information
13:45 EDTANGOAngioDynamics technical commentary before earnings
Subscribe for More Information
April 7, 2015
15:44 EDTNVONovo Nordisk announces FDA accepts Tresiba, Ryzodeg resubmissions for review
Novo Nordisk announced that the U.S. FDA has accepted for review the Class II Resubmissions for Tresiba and Ryzodeg. To preserve the integrity of the ongoing DEVOTE trial, only a small team within Novo Nordisk has access to the data. This team has prepared the interim analysis for the Class II resubmission and will interact with the FDA during the review, on matters related to the interim analysis. As previously communicated, the result of an interim analysis carries a higher level of uncertainty than the final study results as this preliminary estimate is built on a substantially lower number of observations. Accordingly, the relative risk estimate derived from the interim analysis is thus only an indication of the final trial results. Novo Nordisk management does not have access to the results of the interim analysis. The trial is expected to be completed in the second half of 2016.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use